Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 7Stomach Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Neoplasms 2Rectal Neoplasms 1Rectal Diseases 1Intestinal Neoplasms 1Intestinal Diseases 1HER2+ Metastatic Breast Cancer (MBC) 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Colorectal Neoplasms 1Colonic Neoplasms 1Colonic Diseases 1Brain Neoplasms 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

trametinib 4dabrafenib 4encorafenib 3Oxaliplatin 3zolbetuximab 2selpercatinib 2pembrolizumab 2lenvatinib 2larotrectinib 2dostarlimab 2binimetinib 2Leucovorin 2Fulvestrant 2Fluorouracil 2Cetuximab 2Capecitabine 2trastuzumab deruxtecan 1tepotinib 1telisotuzumab vedotin 1ribociclib 1repotrectinib 1relatlimab 1pralsetinib 1pegaspargase 1niraparib 1blinatumomab 1avelumab 1asparaginase erwinia chrysanthemi recombinant 1adagrasib 1Vemurafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Neoplasms × Capecitabine × Clear all
NCT03653507 2026-04-17

GLOW

Astellas Pharma Inc

Phase 3 Active not recruiting
507 enrolled 65 charts 1 FDA
Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Pfizer

Phase 3 Active not recruiting
831 enrolled 2 FDA
Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡